BCL-2 inhibition in follicular lymphoma: can we tip the scales?

Abstract

In this issue of Blood, Zinzani et al1 report the results of the open-label phase 2 CONTRALTO study, which evaluated the additional benefit of adding the BCL-2 inhibitor, venetoclax (VEN), to common treatment backbones, such as rituximab and bendamustine plus rituximab, in patients with relapsed/ refractory follicular lymphoma (FL).